Innova Captab Ltd
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
- Market Cap ₹ 5,705 Cr.
- Current Price ₹ 997
- High / Low ₹ 1,034 / 608
- Stock P/E 68.1
- Book Value ₹ 155
- Dividend Yield 0.20 %
- ROCE 10.8 %
- ROE 9.85 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 6.55 times its book value
- Company has a low return on equity of 11.5% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 4.56% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 373 | 411 | 785 | 859 | 865 | 958 | 1,299 | |
| 322 | 356 | 687 | 760 | 755 | 836 | 1,147 | |
| Operating Profit | 51 | 54 | 99 | 99 | 110 | 122 | 151 |
| OPM % | 14% | 13% | 13% | 11% | 13% | 13% | 12% |
| 1 | 1 | 3 | 9 | 9 | 17 | 13 | |
| Interest | 5 | 4 | 5 | 18 | 14 | 2 | 15 |
| Depreciation | 10 | 6 | 7 | 11 | 11 | 17 | 37 |
| Profit before tax | 38 | 46 | 89 | 78 | 94 | 120 | 112 |
| Tax % | 26% | 26% | 25% | 26% | 27% | 25% | 25% |
| 28 | 34 | 66 | 58 | 68 | 89 | 84 | |
| EPS in Rs | 232.42 | 287.50 | 551.50 | 11.99 | 11.91 | 15.63 | 14.62 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 14% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 15% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 14% |
| TTM: | -7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 11% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 48 | 57 | 57 | 57 |
| Reserves | 98 | 133 | 199 | 220 | 666 | 756 | 829 |
| 54 | 45 | 176 | 237 | 244 | 329 | 321 | |
| 81 | 178 | 157 | 173 | 187 | 223 | 339 | |
| Total Liabilities | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,547 |
| 73 | 79 | 161 | 161 | 164 | 637 | 648 | |
| CWIP | 0 | 7 | 0 | 22 | 339 | 21 | 15 |
| Investments | 0 | 0 | 60 | 60 | 60 | 60 | 101 |
| 172 | 282 | 322 | 435 | 593 | 647 | 782 | |
| Total Assets | 245 | 368 | 544 | 678 | 1,155 | 1,365 | 1,547 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 31 | 42 | 58 | 39 | 112 | 20 | 34 | |
| -6 | -20 | -188 | -88 | -472 | -100 | -14 | |
| -23 | -19 | 125 | 51 | 368 | 84 | -34 | |
| Net Cash Flow | 1 | 3 | -5 | 3 | 8 | 4 | -14 |
| Free Cash Flow | 27 | 23 | -21 | -39 | -165 | -141 | -28 |
| CFO/OP | 79% | 101% | 80% | 59% | 123% | 32% | 36% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 85 | 123 | 81 | 98 | 92 | 95 | 93 |
| Inventory Days | 84 | 107 | 63 | 67 | 68 | 94 | 103 |
| Days Payable | 92 | 132 | 84 | 102 | 111 | 119 | 145 |
| Cash Conversion Cycle | 77 | 99 | 60 | 63 | 49 | 70 | 51 |
| Working Capital Days | 45 | 39 | 23 | 44 | 58 | 65 | 82 |
| ROCE % | 28% | 33% | 21% | 15% | 12% | 11% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Number of CDMO Customers count |
|
|||||
| Total Product Portfolio count |
||||||
| Number of Countries Exported To count |
||||||
| Pharmacy Touchpoints in India count |
||||||
| Baddi Plant Capacity Utilization % |
||||||
| R&D Scientists and Engineers count |
||||||
| Jammu Plant Capacity Utilization % |
||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
3 Jul - Submitted Regulation 74(5) certificate for quarter ended 30 June 2026; no dematerialization requests received.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
25 Jun - Pursuant to the regulation 30 read with schedule III, Part A, Para A of SEBI LODR Regulations, 2015, as amended, we are enclosing herewith copies …
-
Closure of Trading Window
25 Jun - Trading window closed from 1 July 2026 until 48 hours after Q1 FY2027 results.
-
Intimation Of Postponement Of The 22Nd Annual General Meeting Of The Company
24 Jun - Innova Captab postpones its 22nd AGM scheduled for 29 June 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Jun - Pursuant to regulation 30 read with schedule III Part A Para A and Regulation 47 of SEBI (LODR) 2015 as amended time to time and …
Annual reports
Concalls
-
May 2026Transcript PPT REC
-
Feb 2026TranscriptPPT
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT REC
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT
Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain